Abstract: The coronavirus SARS-Cov-2 which started in Wuhan, China, in December 2019 induced a threat to global health. Patients with mental disorders were thought to be at increased risk of becoming infected for several reasons but very much to the inventors' surprise, these psychiatric units remained nearly empty during the lock-down period as if psychiatric patients were protected from SARS-Cov-2 infection. Thus the inventors mined the literature to identify approved drugs with in vitro antiviral activities with a special emphasis on psychotropic drugs and compared these molecules using chemoinformatics strategies to the drugs most commonly used in their psychiatric department. A large number of compounds were found to be cationic amphiphilic drugs (CADs) and as such tend to also be phospholipidosis inducers in vitro (PLD). Several molecules most commonly used in their department were also found to have in vitro antiviral activity and/or can be clustered with compounds with known in vitro antiviral activity.

Abstract: The present invention relates to a genetically modified human stem cell, in which said human stem cell comprises an exogenous nucleic acid comprising a region coding for a fusion protein comprising a mutant human cytochrome P450 2B6 (CYP2B6*) protein of SEQ ID No. 1 or a variant or fragment thereof and an NADPH-cytochrome P450 reductase protein of SEQ ID No. 2 or a variant or fragment thereof, functionally bound to a promoter, said exogenous nucleic acid having been integrated into one of the genomic safe harbors of said human stem cell. The invention also relates to the use of said cell for the treatment of cancer and/or cancer recurrences and/or associated metastases, particularly the solid tumours, and in particular the hepatocellular carcinomas and/or associated metastases.

Abstract: A method for adapting the operation of an apparatus connected to a network deployed in an environment, including the steps of: collecting data relating to the environment from a plurality of sources; identifying usual environmental situations from an analysis of the collected data; detecting a deviation from at least one identified usual situation; and sending a control to the apparatus for adapting the operation thereof to the detected deviation.

Abstract: The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy.

Abstract: The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy.

Abstract: A method for adapting the operation of an apparatus connected to a network deployed in an environment, including the steps of: collecting data relating to the environment from a plurality of sources; identifying usual environmental situations from an analysis of the collected data; detecting a deviation from at least one identified usual situation; and sending a control to the apparatus for adapting the operation thereof to the detected deviation.

Abstract: The present application relates to a set of new cDNA probes which enables the specific and simultaneous detection of the main fourteen CYP450 isoforms, and to new primers specific to the probes. It also provides transfection vectors, genetically engineered cells and with amplification products derived therefrom. The present application notably encompasses any solid surface such as DNA filters or DNA chips which comprises a cDNA probe or an amplification product of the invention. The products provided thereby enables to evaluate the toxicity or pathogenicity of a product, and to predict drug in vivo interactions or efficiency.